OLUX E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OLUX E (OLUX E).
Clobetasol propionate is a high-potency corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, thereby reducing prostaglandin and leukotriene synthesis, producing anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Primarily metabolized in the liver via CYP3A4, though topical application yields minimal systemic absorption. Metabolism involves reduction and conjugation. |
| Excretion | Primarily hepatic metabolism and renal excretion of metabolites; <5% unchanged in urine. |
| Half-life | Terminal half-life approximately 5-6 hours; clinical context: supports twice-daily dosing. |
| Protein binding | Approximately 90% bound to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Vd ~1.4 L/kg; indicates distribution into total body water with some tissue binding. |
| Bioavailability | Percutaneous absorption ~1-3% via intact skin; higher if occluded or skin compromised. |
| Onset of Action | Topical: clinical improvement noted within 2-3 weeks of regular use. |
| Duration of Action | After discontinuation, effects may persist for 1-2 weeks; relapse occurs if underlying condition remains. |
| Molecular Weight | 466.85 Da |
Topical application of a thin layer to affected areas once or twice daily, not exceeding 50 g per week.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in children under 12 years of age due to increased risk of systemic corticosteroid effects. |
| Geriatric use | Use with caution in elderly patients due to increased susceptibility to skin atrophy and systemic effects; limit use to smallest area and shortest duration. |
| 1st trimester | Avoid use. Topical corticosteroids may increase risk of orofacial clefts if used in first trimester. |
| 2nd trimester | Use only if potential benefit justifies risk. Prolonged or high-potency use may cause fetal growth restriction and adrenal suppression. |
| 3rd trimester | Use only if potential benefit justifies risk. High-potency corticosteroids may cause low birth weight and adrenal suppression in newborn. |
Clinical note
Comprehensive clinical and safety monograph for OLUX E (OLUX E).
| Placental transfer | Corticosteroids cross the placenta with varying degrees. Clobetasol propionate is a high-potency corticosteroid; placental transfer is likely but extent is not well documented. Fetal plasma levels are lower than maternal. |
| Breastfeeding | Topical application of high-potency corticosteroids should be used with caution during breastfeeding. Avoid application to the breast or nipple area to prevent infant ingestion. Use the lowest effective dose for the shortest duration. |
■ FDA Black Box Warning
No FDA boxed warning exists for this topical product.
| Serious Effects |
Hypersensitivity to clobetasol propionate or any components of the formulationUntreated bacterial, fungal, or viral skin infectionsRosaceaPerioral dermatitis
| Precautions | Systemic absorption may produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria., Use should be limited to 2 consecutive weeks and not exceed 50 g/week., Avoid use in patients with skin atrophy, rosacea, perioral dermatitis, or bacterial/fungal infections., Apply only to affected areas; avoid occlusive dressings unless directed., Pediatric patients may be more susceptible to systemic toxicity. |
| Food/Dietary | No clinically significant food interactions. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Olux-E (clobetasol propionate) is a high-potency topical corticosteroid. Systemic absorption is minimal with topical use, but prolonged or extensive use may increase risk. In animal studies, corticosteroids have been shown to be teratogenic (cleft palate, skeletal abnormalities) at relatively low systemic doses. Human data are limited; however, the potential for fetal harm cannot be ruled out. Use during pregnancy only if the potential benefit justifies the risk to the fetus. First trimester: Avoid use unless essential. Second/third trimester: Limited data; avoid large areas, prolonged use, or occlusive dressings. |
| Fetal Monitoring | Monitor maternal adrenal function (e.g., ACTH stimulation test) if prolonged or extensive use occurs. Monitor fetal growth with ultrasound if high-dose or prolonged use during pregnancy. Assess for signs of HPA axis suppression in the neonate if maternal use was high-dose or prolonged. |
| Fertility Effects | No specific data on fertility effects in humans. Animal studies with corticosteroids have shown reduced fertility. Topical clobetasol propionate is unlikely to significantly impact fertility due to minimal systemic absorption. |
| Clinical Pearls | OLUX E (clobetasol propionate 0.05% emollient foam) is a super-high-potency topical corticosteroid. Do not use on the face, groin, or axillae due to risk of atrophy. Limit continuous use to 2 weeks; maximum 50 g/week. Reassess if no improvement after 2 weeks. Foam formulation enhances penetration; apply to scalp psoriasis directly from can, not onto hands first. |
| Patient Advice | Use only as directed; do not use on face, underarms, or groin. · Apply a thin layer to affected areas once in the morning and once at night. · Do not cover with bandages or wraps unless instructed by your doctor. · Wash hands after applying unless treating hands. · Do not use longer than 2 weeks at a time; avoid using on large areas. · Tell your doctor if you develop skin thinning, burning, or infection. · Avoid contact with eyes; if contact occurs, rinse thoroughly with water. · Do not use for diaper rash in children. |